Heidi de Wet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7119624/publications.pdf

Version: 2024-02-01

24 papers

1,375 citations

16 h-index 23 g-index

24 all docs

24 docs citations

times ranked

24

1751 citing authors

#	Article	IF	CITATIONS
1	ATPase and Multidrug Transport Activities of the Overexpressed Yeast ABC Protein Yor1p. Journal of Biological Chemistry, 1998, 273, 12612-12622.	1.6	345
2	3-D structural and functional characterization of the purified KATPchannel complex Kir6.2-SUR1. EMBO Journal, 2005, 24, 4166-4175.	3.5	156
3	SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator. Philosophical Transactions of the Royal Society B: Biological Sciences, 2009, 364, 257-267.	1.8	138
4	A Ketone Ester Drink Lowers Human Ghrelin and Appetite. Obesity, 2018, 26, 269-273.	1.5	123
5	Asymmetric Switching in a Homodimeric ABC Transporter: A Simulation Study. PLoS Computational Biology, 2010, 6, e1000762.	1.5	67
6	Studies of the ATPase activity of the ABC protein SUR1. FEBS Journal, 2007, 274, 3532-3544.	2.2	62
7	Mitogen-Activated Protein Kinase Phosphatase 1/Dual Specificity Phosphatase 1 Mediates Glucocorticoid Inhibition of Osteoblast Proliferation. Molecular Endocrinology, 2007, 21, 2929-2940.	3.7	61
8	Increased ATPase activity produced by mutations at arginine-1380 in nucleotide-binding domain 2 of <i>ABCC8</i> causes neonatal diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18988-18992.	3.3	51
9	Activation of the KATP channel by Mg-nucleotide interaction with SUR1. Journal of General Physiology, 2010, 136, 389-405.	0.9	51
10	Molecular Mechanism of Sulphonylurea Block of KATP Channels Carrying Mutations That Impair ATP Inhibition and Cause Neonatal Diabetes. Diabetes, 2013, 62, 3909-3919.	0.3	44
11	Sequence Requirements of the ATP-Binding Site within the C-Terminal Nucleotide-Binding Domain of Mouse P-Glycoprotein: Structureâ^'Activity Relationships for Flavonoid Bindingâ€. Biochemistry, 2001, 40, 10382-10391.	1.2	41
12	A mutation (R826W) in nucleotideâ€binding domain 1 of <i>ABCC8</i> reduces ATPase activity and causes transient neonatal diabetes. EMBO Reports, 2008, 9, 648-654.	2.0	40
13	Molecular action of sulphonylureas on KATP channels: a real partnership between drugs and nucleotides. Biochemical Society Transactions, 2015, 43, 901-907.	1.6	39
14	Modulation of the BK channel by estrogens: examination at single channel level. Molecular Membrane Biology, 2006, 23, 420-429.	2.0	32
15	MKP-1 Knockout Does not Prevent Glucocorticoid-Induced Bone Disease in Mice. Calcified Tissue International, 2011, 89, 221-227.	1.5	23
16	Sulfonylureas suppress the stimulatory action of Mg-nucleotides on Kir6.2/SUR1 but not Kir6.2/SUR2A KATP channels: A mechanistic study. Journal of General Physiology, 2014, 144, 469-486.	0.9	20
17	Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies. BMC Endocrine Disorders, 2010, 10, 16.	0.9	15
18	The ATPase activities of sulfonylurea receptor $\hat{a} \in f2A$ and sulfonylurea receptor $\hat{a} \in f2B$ are influenced by the Câ \in terminal 42 amino acids. FEBS Journal, 2010, 277, 2654-2662.	2.2	14

#	Article	IF	CITATION
19	A universally conserved residue in the SUR1 subunit of the K ATP channel is essential for translating nucleotide binding at SUR1 into channel opening. Journal of Physiology, 2012, 590, 5025-5036.	1.3	13
20	The ATPase activities of sulfonylurea receptor 2A and sulfonylurea receptor 2B are influenced by the C-terminal 42 amino acids. FEBS Journal, 2010, 277, 2654-2662.	2.2	12
21	Abcc5 Knockout Mice Have Lower Fat Mass and Increased Levels of Circulating GLPâ€1. Obesity, 2019, 27, 1292-1304.	1.5	11
22	Tetrameric structure of SUR2B revealed by electron microscopy of oriented single particles. FEBS Journal, 2013, 280, 1051-1063.	2.2	9
23	Acetyl-CoA-carboxylase 1 (ACC1) plays a critical role in glucagon secretion. Communications Biology, 2022, 5, 238.	2.0	8
24	NMDA Receptor Antagonists Increase the Release of GLP-1 From Gut Endocrine Cells. Frontiers in Pharmacology, 2022, 13, 861311.	1.6	0